Cell-Based Immunotherapies for Cancer and Inflammatory Disease
Cellicure develops high-yield NK cell treatments using our proprietary Effic-NK expansion system and Saftein technology to fight solid tumors, hematological cancers, and chronic inflammatory diseases.
Advanced cell expansion technology for higher therapeutic yield
Cellicure's feeder-free Effic-NK expansion system delivers high-yield NK cell treatments with intact functionality and superior survival rates.
Feeder-free expansion
Simplified culture setup eliminates feeder cells while maintaining high cell expansion efficiency and reducing complexity.
High cellular yield
Cellicure's system achieves superior cell expansion rates, producing greater numbers of functional NK cells per culture cycle.
Intact cell functionality
NK cells maintain full therapeutic capability and potency throughout expansion, ensuring treatment efficacy without functional compromise.
Superior cell survival
Cellicure's Saftein technology provides membrane-bound support equivalent to or better than cytokine-based approaches without associated toxicity.
Reduced toxicity profile
Saftein avoids cytokine-associated toxicity and immunosuppression, enabling safer therapeutic outcomes compared to traditional expansion methods.
Scalable production
Cellicure's system supports efficient scaling from research through clinical manufacturing while maintaining consistent product quality.
Saftein technology enhances NK cell survival and function
Cellicure's membrane-bound Saftein supports NK cell renewal without the toxicity and immunosuppression linked to cytokine therapies, delivering superior therapeutic outcomes.
What our clients say
Cellicure's cell-based immunotherapies are delivering meaningful clinical outcomes for patients and partners worldwide.
Cellicure's Effic-NK expansion system significantly improved our manufacturing efficiency while maintaining the high cell functionality we require for patient treatment.
Dr. James Mitchell
Clinical Development Director, Leading Cancer Research Institution
The feeder-free culture system reduced our operational complexity dramatically. Cellicure's support team understood our challenges and delivered solutions that worked.
Dr. Sarah Chen
Manufacturing Operations Manager, Immunotherapy Research Center
Saftein technology eliminated the toxicity issues we were managing with cytokine-based approaches. Our NK cell products now show superior survival and functionality.
Dr. Robert Oluwaseun
Chief Scientific Officer, Cellular Therapy Institute
Cellicure's high-yield NK cell production enabled us to scale our clinical programs without compromising cell quality. The partnership has been seamless.
Dr. Maria Gonzalez
Head of Cell Therapy Development, Academic Medical Center
Cellicure's cell-based immunotherap y packages
Flexible service tiers designed to meet clinical development needs. From early-stage research to advanced therapeutic protocols.
Research collaboration
Custom
project-basedEarly-stage partnership for preclinical development and feasibility studies using Effic-NK expansion technology.
Features:
Development program
Custom
12-monthComprehensive cell expansion and optimization program with Saftein-enhanced NK cell production and clinical readiness preparation.
Features:
Manufacturing services
Custom
per batchLicensed manufacturing of Cellicure's high-yield NK cell treatments for approved clinical applications and ongoing supply.
Features:
License & partnership
Custom
negotiatedTechnology licensing and strategic partnership opportunities for organizations developing cell-based treatments independently.
Features:
Questions about our cell therapies?
Find answers about Cellicure's Effic-NK expansion system, Saftein technology, and immunotherapy treatments.
What makes Cellicure's NK cell expansion system different?
Cellicure's Effic-NK system is feeder-free with a simplified culture setup, delivering high cell yield while maintaining intact functionality. Unlike cytokine-based therapies, our NK cells achieve superior survival and renewal without the toxicity concerns.
How does Saftein technology improve NK cell treatment?
Saftein is a membrane-bound technology expressed on NK cell surfaces that supports cell survival and renewal equal to or better than current cytokine approaches. It eliminates the immunosuppression and toxicity issues commonly seen with cytokine use.
Which conditions does Cellicure's therapy address?
Cellicure develops cell-based immunotherapies for solid tumors, hematological cancers, and chronic inflammatory diseases. Our treatments target unmet clinical needs where conventional therapies fall short.
What is the development timeline for Cellicure's treatments?
Cellicure conducts global product development and commercialization for cell-based immunotherapies. Timelines vary by indication and regulatory pathway. Contact us to discuss specific programs and their development status.
How does Cellicure's approach differ from other cell therapy companies?
Our feeder-free Effic-NK system simplifies manufacturing while achieving high efficiency and cell yield. Combined with Saftein technology, we deliver functional NK cells without the toxicity burden of traditional cytokine-based therapies.
Can I learn more about clinical applications and partnerships?
Cellicure partners globally for product development and commercialization. Reach out to our team to discuss your interest in our therapies, potential collaborations, or to receive detailed program information.
Still have questions?
Contact our team to discuss Cellicure's cell-based immunotherapies and how they may address your needs.